Showing results (11-20 of 18) with videos related to

Sort By:
Pageof 2
You have reached the last page of results.This site can display upto 18 results.
Transplantation and Cellular Therapy|April 7, 2022
Impact of Center Experience with Donor Type on Outcomes: A Secondary Analysis, Blood and Marrow Transplant Clinical Trials Network 1101Open for Accrual June 2012Open for Accrual June 2012Claudio G Brunstein, Paul V O'Donnell, Brent Logan, et al.
Blood|February 14, 2018
α1-Antitrypsin infusion for treatment of steroid-resistant acute graft-versus-host diseaseJohn M Magenau, Steven C Goldstein, Dan Peltier, et al.
Transplantation and Cellular Therapy|November 14, 2021
Umbilical Cord Blood or HLA-Haploidentical Transplantation: Real-World Outcomes versus Randomized Trial OutcomesPaul V O'Donnell, Claudio G Brunstein, Ephraim J Fuchs, et al.
The New England Journal of Medicine|December 4, 2018
Tisagenlecleucel in Adult Relapsed or Refractory Diffuse Large B-Cell LymphomaStephen J Schuster, Michael R Bishop, Constantine S Tam, et al.
The Lancet. Oncology|December 4, 2013
Vorinostat plus tacrolimus and mycophenolate to prevent graft-versus-host disease after related-donor reduced-intensity conditioning allogeneic haemopoietic stem-cell transplantation: a phase 1/2 trialSung Won Choi, Thomas Braun, Lawrence Chang, et al.
Blood|December 12, 2025
Orca-T versus allogeneic hematopoietic stem cell transplantation (PRECISION-T): a multicenter, randomized phase 3 trialEverett Meyer, Amandeep Salhotra, Arpita Gandhi, et al.
Journal of the National Comprehensive Cancer Network : JNCCN|October 9, 2025
Hematopoietic Cell Transplantation, Version 3.2025, NCCN Clinical Practice Guidelines In OncologyAlison W Loren, Marco Mielcarek, Javier Bolaños-Meade, et al.
Blood|February 4, 2026
A phase 1/2 study of donor-derived anti-CD33 CAR T-cell therapy (VCAR33) for relapsed/refractory AML after allogeneic HCTMuhammad Umair Mushtaq, John F DiPersio, Jacques Azzi, et al.
Pageof 2